A JavaScript Runtime Error Occurred :0

Need help? Email the Webmaster

  • Overview
  • FAQ
  • Billing Catalog


The Center for Advanced Preclinical Research (CAPR) was established in 2008 and is currently directed by Shyam K. Sharan, Ph.D. The large majority of CAPR collaborations are with CCR and NCI researchers on projects selected through a yearly Request for Applications (RFA) wherein proposals are reviewed and approved by CAPR’s scientific oversight committee. CAPR is not a fee for service or core facility, but rather a CCR resource that specializes in evaluating the efficacy of preclinical compounds, existing drugs, or biologics (therapeutics) in genetically engineered mouse (GEM) models, GEM-derived allograft (GDA) models, or patient-derived mouse xenografts (PDX).  CAPR’s operating structure is a novel hybrid culture of integrated research rigor and project/goal management.  CAPR has integrated expertise in cancer mechanisms, pathways, murine models, genetics, drug development, and stem cell biology.

 In Vivo

  • Adaptation of GEM models to syngeneic allograft models

  • Evaluation of therapeutic candidates in efficacy studies

  • Immunohistochemical stains

  • Establish and evaluate novel PDX models

  • GEM engineering

  • Characterization and validation of GEM models

  • GEM model re-tooling/refinement

  • Surgical techniques for generation of murine orthotopic transplant model cohorts

  • Pharmacokinetics and biodistribution of therapeutics in animal models

  • Pharmacodynamics: evaluation of drug effect on intended target in tumor tissue

  • Cancer prevention studies in GEM models

  • Biomarkers/molecular signatures of treatment response

 In Vitro

  • Primary tumor cell culture establishment

  • iPSC technologies

  • cell viability assays

  • CRISPR and recombineering allele construction

  • Histopathological assessment

  • Quantitative molecular pathology

  • Evaluation of drug target inhibition




        Billing Catalog

        The following validation errors have occurred: